Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas
Language English Country United States Media print-electronic
Document type Clinical Study, Journal Article, Multicenter Study
PubMed
27614935
DOI
10.1002/jca.21506
Knihovny.cz E-resources
- Keywords
- relapsed lymphomas, stem cell mobilization,
- MeSH
- Transplantation, Autologous MeSH
- Adult MeSH
- Clinical Audit MeSH
- Peripheral Blood Stem Cells pathology MeSH
- Combined Modality Therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphoma blood drug therapy therapy MeSH
- Adolescent MeSH
- Young Adult MeSH
- Hematopoietic Stem Cell Mobilization methods MeSH
- Treatment Failure MeSH
- Prospective Studies MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Recurrence MeSH
- Aged MeSH
- Peripheral Blood Stem Cell Transplantation MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Study MeSH
- Multicenter Study MeSH
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) to rescue hematopoiesis is considered standard care for patients with a relapsed chemosensitive lymphoma, but diagnosis of lymphoma has been a risk factor for poor mobilization in several studies. The aim of this prospective noninterventional clinical audit was to review the mobilization strategies used by EBMT centers in relapsed lymphoma and to evaluate their efficacy. Between 2010 and 2014, 275 patients with relapsed lymphoma from 30 EBMT centers were prospectively registered. Almost all patients were mobilized with chemotherapy plus G-CSF (96%), but there was a large variation in chemotherapy schedules. Thirty (11%) of them were poor mobilizers (<2 × 106 CD 34+ cells/kg body weight) at the first mobilization. Poor mobilization was not associated with gender, age, bone marrow involvement at diagnosis, primary diagnosis, number of previous chemotherapy lines, previous radiotherapy or mobilization with G-CSF alone. The use of high dose cyclophosphamide alone was associated with mobilization failure (P = 0.0006), whereas the use of a platinum-containing regimen was associated with a good mobilization outcome (P = 0.013). Because failure rate is low, we can conclude from this study that PBSC mobilization failure in relapsed lymphomas is not an important problem in the EBMT centers.
Department of Hematology Gazi University Ankara Turkey
Department of Hematology Maastricht University Medical Center Maastricht The Netherlands
Department of Hematology Radboud University Medical Centre Nijmegen The Netherlands
Department of Internal Medicine 5 University of Heidelberg Heidelberg Germany
Department of Medicine 3 Klinikum Karlsruhe Karlsruhe Germany
Department of Medicine Charles University Hospital Prague Czech Republic
EBMT Lymphoma Working Party Paris France
Hematology Department Institut Catala d'Oncologia Hospital Duran 1 Reynals Barcelona Spain
References provided by Crossref.org